{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T16:10:15Z","timestamp":1741882215085,"version":"3.38.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T00:00:00Z","timestamp":1719014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T00:00:00Z","timestamp":1719014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-024-03177-8","type":"journal-article","created":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T12:01:37Z","timestamp":1719057697000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic factors for intravitreal conbercept in the treatment of choroidal neovascularization secondary to pathological myopia"],"prefix":"10.1007","volume":"44","author":[{"given":"Dingding","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunfang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wangbin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,22]]},"reference":[{"issue":"1","key":"3177_CR1","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41572-020-00231-4","volume":"6","author":"PN Baird","year":"2020","unstructured":"Baird PN, Saw SM, Lanca C et al (2020) Myopia. Nat Rev Dis Prim 6(1):99","journal-title":"Nat Rev Dis Prim"},{"issue":"3","key":"3177_CR2","doi-asserted-by":"publisher","first-page":"M1","DOI":"10.1167\/iovs.18-25980","volume":"60","author":"JS Wolffsohn","year":"2019","unstructured":"Wolffsohn JS, Flitcroft DI, Gifford KL et al (2019) IMI\u2013myopia control reports overview and introduction. Invest Ophthalmol Vis Sci 60(3):M1\u2013M19","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"3177_CR3","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.survophthal.2014.10.002","volume":"60","author":"FA Adatia","year":"2015","unstructured":"Adatia FA, Luong M, Munro M, Tufail A (2015) The other CNVM: a review of myopic choroidal neovascularization treatment in the age of anti-vascular endothelial growth factor agents. Surv Ophthalmol 60(3):204\u2013215","journal-title":"Surv Ophthalmol"},{"issue":"1","key":"3177_CR4","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1097\/ICL.0000000000000201","volume":"42","author":"NS-W Chan","year":"2016","unstructured":"Chan NS-W, Teo K, Cheung CMG (2016) Epidemiology and diagnosis of myopic choroidal neovascularization in Asia. Eye Contact Lens 42(1):48\u201355","journal-title":"Eye Contact Lens"},{"key":"3177_CR5","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.preteyeres.2017.10.005","volume":"63","author":"K Ohno-Matsui","year":"2018","unstructured":"Ohno-Matsui K, Ikuno Y, Lai TYY, Gemmy Cheung CM (2018) Diagnosis and treatment guideline for myopic choroidal neovascularization due to pathologic myopia. Prog Retin Eye Res 63:92\u2013106","journal-title":"Prog Retin Eye Res"},{"issue":"6","key":"3177_CR6","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.ophtha.2017.12.005","volume":"125","author":"Y Fang","year":"2018","unstructured":"Fang Y, Yokoi T, Nagaoka N et al (2018) Progression of myopic maculopathy during 18-year follow-up. Ophthalmology 125(6):863\u2013877","journal-title":"Ophthalmology"},{"issue":"8","key":"3177_CR7","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1016\/j.ophtha.2009.11.003","volume":"117","author":"K Hayashi","year":"2010","unstructured":"Hayashi K, Ohno-Matsui K, Shimada N et al (2010) Long-term pattern of progression of myopic maculopathy: a natural history study. Ophthalmology 117(8):1595\u2013611.e1-4","journal-title":"Ophthalmology"},{"issue":"9","key":"3177_CR8","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.2174\/1389450122999210128180725","volume":"22","author":"L Toto","year":"2021","unstructured":"Toto L, Di Antonio L, Costantino O, Mastropasqua R (2021) Anti-VEGF therapy in myopic CNV. Curr Drug Targets 22(9):1054\u20131063","journal-title":"Curr Drug Targets"},{"issue":"12","key":"3177_CR9","first-page":"Cd011160","volume":"12","author":"Y Zhu","year":"2016","unstructured":"Zhu Y, Zhang T, Xu G, Peng L (2016) Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia. Cochrane Database Syst Rev 12(12):Cd011160","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"3177_CR10","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s40265-016-0605-0","volume":"76","author":"KYC Teo","year":"2016","unstructured":"Teo KYC, Ng WY, Lee SY, Cheung CMG (2016) Management of myopic choroidal neovascularization: focus on anti-VEGF therapy. Drugs 76(11):1119\u20131133","journal-title":"Drugs"},{"issue":"11","key":"3177_CR11","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1016\/j.ophtha.2017.04.028","volume":"124","author":"CMG Cheung","year":"2017","unstructured":"Cheung CMG, Arnold JJ, Holz FG et al (2017) Myopic choroidal neovascularization: review, guidance, and consensus statement on management. Ophthalmology 124(11):1690\u20131711","journal-title":"Ophthalmology"},{"issue":"12","key":"3177_CR12","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1080\/02713683.2020.1781193","volume":"45","author":"H Liu","year":"2020","unstructured":"Liu H, Ma Y, Xu HC, Huang LY, Zhai LY, Zhang XR (2020) Updates on the management of ocular vasculopathies with VEGF inhibitor conbercept. Curr Eye Res 45(12):1467\u20131476","journal-title":"Curr Eye Res"},{"issue":"12","key":"3177_CR13","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1080\/14712598.2021.1830969","volume":"20","author":"DSC Ng","year":"2020","unstructured":"Ng DSC, Fung NSK, Yip FLT, Lai TYY (2020) Ranibizumab for myopic choroidal neovascularization. Expert Opin Biol Ther 20(12):1385\u20131393","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"3177_CR14","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s10384-014-0363-z","volume":"59","author":"SY Cohen","year":"2015","unstructured":"Cohen SY, Nghiem-Buffet S, Grenet T et al (2015) Long-term variable outcome of myopic choroidal neovascularization treated with ranibizumab. Jpn J Ophthalmol 59(1):36\u201342","journal-title":"Jpn J Ophthalmol"},{"issue":"7","key":"3177_CR15","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1097\/IAE.0000000000002164","volume":"39","author":"Y Onishi","year":"2019","unstructured":"Onishi Y, Yokoi T, Kasahara K et al (2019) Five-year outcomes of intravitreal ranibizumab for choroidal neovascularization in patients with pathologic myopia. Retina 39(7):1289\u20131298","journal-title":"Retina"},{"issue":"4","key":"3177_CR16","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s00417-018-04214-w","volume":"257","author":"K Sayanagi","year":"2019","unstructured":"Sayanagi K, Uematsu S, Hara C et al (2019) Effect of intravitreal injection of aflibercept or ranibizumab on chorioretinal atrophy in myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 257(4):749\u2013757","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"9","key":"3177_CR17","doi-asserted-by":"publisher","first-page":"e0273613","DOI":"10.1371\/journal.pone.0273613","volume":"17","author":"KW Bae","year":"2022","unstructured":"Bae KW, Kim DI, Kim BH et al (2022) Risk factors for myopic choroidal neovascularization-related macular atrophy after anti-VEGF treatment. PLoS ONE 17(9):e0273613","journal-title":"PLoS ONE"},{"issue":"12","key":"3177_CR18","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1097\/IAE.0000000000000610","volume":"35","author":"DS Ng","year":"2015","unstructured":"Ng DS, Kwok AK, Tong JM, Chan CW, Li WW (2015) Factors influencing need for retreatment and long-term visual outcome after intravitreal bevacizumab for myopic choroidal neovascularization. Retina 35(12):2457\u20132468","journal-title":"Retina"},{"issue":"3","key":"3177_CR19","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s00417-015-3076-1","volume":"254","author":"V Sarao","year":"2016","unstructured":"Sarao V, Veritti D, Macor S, Lanzetta P (2016) Intravitreal bevacizumab for choroidal neovascularization due to pathologic myopia: long-term outcomes. Graefes Arch Clin Exp Ophthalmol 254(3):445\u2013454","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3177_CR20","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1007\/s10792-023-02755-6","volume":"43","author":"M Woronkowicz","year":"2023","unstructured":"Woronkowicz M, Hamilton R, Lightman S, Zagora S, Tomkins-Netzer O (2023) Comparison of anatomical and functional outcomes of treating myopic choroidal neovascularization with bevacizumab or ranibizumab. Int Ophthalmol 43:3499\u20133507","journal-title":"Int Ophthalmol"},{"issue":"11","key":"3177_CR21","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1097\/IAE.0000000000001456","volume":"37","author":"E Bruy\u00e8re","year":"2017","unstructured":"Bruy\u00e8re E, Miere A, Cohen SY et al (2017) Neovascularization secondary to high myopia imaged by optical coherence tomography angiography. Retina 37(11):2095\u20132101","journal-title":"Retina"},{"issue":"4","key":"3177_CR22","doi-asserted-by":"publisher","first-page":"e0216304","DOI":"10.1371\/journal.pone.0216304","volume":"14","author":"Y Nakano","year":"2019","unstructured":"Nakano Y, Kataoka K, Takeuchi J et al (2019) Vascular maturity of type 1 and type 2 choroidal neovascularization evaluated by optical coherence tomography angiography. PLoS ONE 14(4):e0216304","journal-title":"PLoS ONE"},{"issue":"1","key":"3177_CR23","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s12886-021-01877-8","volume":"21","author":"X Nie","year":"2021","unstructured":"Nie X, Wang Y, Yi H, Qiao Y (2021) Intravitreal conbercept for choroidal neovascularisation secondary to pathological myopia in a real-world setting in China: intravitreal conbercept was safe and effective in treating myopic choroidal neovascularization. BMC Ophthalmol 21(1):116","journal-title":"BMC Ophthalmol"},{"issue":"3","key":"3177_CR24","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s40123-021-00354-1","volume":"10","author":"R Anguita","year":"2021","unstructured":"Anguita R, Tasiopoulou A, Shahid S, Roth J, Sim SY, Patel PJ (2021) A review of aflibercept treatment for macular disease. Ophthalmol Ther 10(3):413\u2013428","journal-title":"Ophthalmol Ther"},{"issue":"6","key":"3177_CR25","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3892\/etm.2023.12000","volume":"25","author":"W Zhu","year":"2023","unstructured":"Zhu W, Hao Y, Yuan Z, Huang C (2023) High-dose aflibercept injection has striking effects on myopic choroidal neovascularization. Exp Ther Med 25(6):301","journal-title":"Exp Ther Med"},{"issue":"1","key":"3177_CR26","doi-asserted-by":"publisher","first-page":"7337","DOI":"10.1038\/s41598-021-86835-6","volume":"11","author":"HY Wang","year":"2021","unstructured":"Wang HY, Tao MZ, Wang XX et al (2021) Baseline characteristics of myopic choroidal neovascularization in patients above 50 years old and prognostic factors after intravitreal conbercept treatment. Sci Rep 11(1):7337","journal-title":"Sci Rep"},{"issue":"10","key":"3177_CR27","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.3390\/ph14101042","volume":"14","author":"F Mallone","year":"2021","unstructured":"Mallone F, Giustolisi R, Franzone F et al (2021) Ten-year outcomes of intravitreal bevacizumab for myopic choroidal neovascularization: analysis of prognostic factors. Pharmaceuticals (Basel) 14(10):1042","journal-title":"Pharmaceuticals (Basel)"},{"issue":"3","key":"3177_CR28","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1097\/IAE.0000000000003675","volume":"43","author":"M Ravenstijn","year":"2023","unstructured":"Ravenstijn M, Klaver CCW, Yzer S (2023) Long-term treatment outcomes after bevacizumab therapy for macular neovascularization in White patients with high myopia. Retina 43(3):444\u2013453","journal-title":"Retina"},{"issue":"10","key":"3177_CR29","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.3390\/diagnostics13101820","volume":"13","author":"F Bat\u0131o\u011flu","year":"2023","unstructured":"Bat\u0131o\u011flu F, Yan\u0131k \u00d6, Demirel S, \u00d6zmert E (2023) Clinical use of optical coherence tomography angiography in retinal diseases. Diagnostics (Basel) 13(10):1820","journal-title":"Diagnostics (Basel)"},{"issue":"3","key":"3177_CR30","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1038\/s41433-020-0979-9","volume":"35","author":"T Ramakrishnan","year":"2021","unstructured":"Ramakrishnan T, Chandra S, Sivaprasad S (2021) Long-term follow-up of management of choroidal neovascularisation secondary to angioid streaks with intravitreal anti-vascular endothelial growth factor. Eye (Lond) 35(3):853\u2013857","journal-title":"Eye (Lond)"},{"key":"3177_CR31","doi-asserted-by":"publisher","first-page":"720804","DOI":"10.3389\/fmed.2021.720804","volume":"8","author":"H Lu","year":"2021","unstructured":"Lu H, Yue T, Liu N et al (2021) Efficacy of Conbercept in the treatment of choroidal neovascularization secondary to pathologic myopia. Front Med 8:720804","journal-title":"Front Med"},{"issue":"5","key":"3177_CR32","doi-asserted-by":"publisher","first-page":"e813","DOI":"10.1111\/aos.13632","volume":"97","author":"M Yan","year":"2019","unstructured":"Yan M, Huang Z, Lian HY, Song YP, Chen X (2019) Conbercept for treatment of choroidal neovascularization secondary to pathologic myopia. Acta Ophthalmol 97(5):e813\u2013e814","journal-title":"Acta Ophthalmol"},{"issue":"7","key":"3177_CR33","doi-asserted-by":"publisher","first-page":"300060523118793","DOI":"10.1177\/03000605231187933","volume":"51","author":"A Javed","year":"2023","unstructured":"Javed A, Khanna A, Palmer E et al (2023) Optical coherence tomography angiography: a review of the current literature. J Int Med Res 51(7):3000605231187933","journal-title":"J Int Med Res"},{"issue":"10","key":"3177_CR34","doi-asserted-by":"publisher","first-page":"3445","DOI":"10.1007\/s10792-023-02655-9","volume":"43","author":"L Song","year":"2023","unstructured":"Song L, Luo C, Zheng Y, Sha X (2023) Clinical outcomes of different regimens of intravitreal Conbercept for the treatment of choroidal neovascularization secondary to pathological myopia. Int Ophthalmol 43(10):3445\u20133452","journal-title":"Int Ophthalmol"},{"key":"3177_CR35","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ajo.2018.08.026","volume":"197","author":"K Liu","year":"2019","unstructured":"Liu K, Song Y, Xu G et al (2019) Conbercept for treatment of neovascular age-related macular degeneration: results of the randomized phase 3 PHOENIX study. Am J Ophthalmol 197:156\u2013167","journal-title":"Am J Ophthalmol"},{"key":"3177_CR36","doi-asserted-by":"publisher","first-page":"696201","DOI":"10.3389\/fphar.2021.696201","volume":"12","author":"P Zhou","year":"2021","unstructured":"Zhou P, Zheng S, Wang E, Men P, Zhai S (2021) Conbercept for treatment of neovascular age-related macular degeneration and visual impairment due to diabetic macular edema or pathologic myopia choroidal neovascularization: a systematic review and meta-analysis. Front Pharmacol 12:696201","journal-title":"Front Pharmacol"},{"key":"3177_CR37","doi-asserted-by":"publisher","first-page":"118795","DOI":"10.1016\/j.lfs.2020.118795","volume":"265","author":"JP Xia","year":"2021","unstructured":"Xia JP, Liu SQ, Wang S (2021) Intravitreal conbercept improves outcome of proliferative diabetic retinopathy through inhibiting inflammation and oxidative stress. Life Sci 265:118795","journal-title":"Life Sci"},{"issue":"5","key":"3177_CR38","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1111\/ceo.12781","volume":"44","author":"D Ferrara","year":"2016","unstructured":"Ferrara D (2016) Image artifacts in optical coherence tomography angiography. Clin Exp Ophthalmol 44(5):367\u2013368","journal-title":"Clin Exp Ophthalmol"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-024-03177-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-024-03177-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-024-03177-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T15:45:20Z","timestamp":1741880720000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-024-03177-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,22]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3177"],"URL":"https:\/\/doi.org\/10.1007\/s10792-024-03177-8","relation":{},"ISSN":["1573-2630"],"issn-type":[{"type":"electronic","value":"1573-2630"}],"subject":[],"published":{"date-parts":[[2024,6,22]]},"assertion":[{"value":"12 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to disclose relevant to this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study was approved by the ethics committee of Huizhou Municipal Central Hospital. Written informed consent was waived due to the retrospective nature of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The Research Ethics Board approved our request to publish anonymized data for this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No informed consent was obtained from participants as data collected were retrospective in nature and part of the standard of care examination. This was approved by the ethics committee of Huizhou Municipal Central Hospital and adhered to the Tenet\u2019s of Helsinki for retrospective studies.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"253"}}